1.97
1.97 (0%)
As of Nov 07, 2024
Trevena Inc [TRVN]
Source:
Company Overview
We are a biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
| Country | United States |
| Headquarters | chesterbrook, pennsylvania |
| Phone Number | 6103548840 |
| Industry | manufacturing |
| CEO | Carrie L. Bourdow |
| Website | www.olinvyk.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.3 |
| Operating Profit | $-6.5 |
| Net Income | $-4.9 |
| Net Cash | $-16.6 |
Profit Ratios
| Gross Margin | $0.2 |
| Operating Margin | -2,000.9 |
| Profit as % of Revenues | -4.5% |
| Profit as % of Assets | -42% |
| Profit as % of Stockholder Equity | 25.8% |
Management Effectiveness
| Return on Equity | 25.8% |
| Return on Assets | -21.3% |
| Turnover Ratio | 2.8% |
| EBITA | $-6.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $22.9 |
| Total Liabilities | $41.9 |
| Operating Cash Flow | $-16.6 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $-0 |
